文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

肾脏疾病中的糖基化作用。

Glycosylation in kidney diseases.

作者信息

Ling Yingying, Cai Fei, Su Tao, Zhong Yi, Li Ling, Meng Bo, Li Guisen, Gong Meng, Yang Hao, Xie Xinfang, Sun Zhenyu, Zhao Yang, Liu Fang, Zhang Yong

机构信息

Department of Nephrology, Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China.

Department of Nephrology, Institute of Kidney Diseases, West China Hospital, Sichuan University, Chengdu 610041, China.

出版信息

Precis Clin Med. 2025 Jul 11;8(3):pbaf017. doi: 10.1093/pcmedi/pbaf017. eCollection 2025 Sep.


DOI:10.1093/pcmedi/pbaf017
PMID:40852041
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12368498/
Abstract

Protein glycosylation is a critical post-translational modification that influences protein folding, localization, stability, and functional interactions by attaching glycans to specific sites. This process is crucial for biological functions of glycoproteins, and aberrant glycosylation can lead to genetic disorders, immune system issues, and multi-organ pathologies. Recent advancements in glycoproteomic technologies have made the study of protein glycosylation a key focus for understanding the pathogenesis of kidney diseases. This review provides a comprehensive overview of protein glycosylation mechanisms, its biological roles, molecular pathways, and significant functions in renal physiology and pathology. It specifically highlights the dynamic changes and regulatory networks associated with aberrant glycosylation in kidney diseases such as immunoglobulin A nephropathy, diabetic kidney disease, autosomal dominant polycystic kidney disease, renal cell carcinoma, and acute kidney injury. It also evaluates the clinical applications of related technologies and biomarkers. Additionally, it discusses the challenges in developing glycosylation-targeted therapeutic strategies. Future research should focus on clarifying cell-specific glycosylation regulatory networks in the kidney, integrating glycobiology with multi-omics approaches, and improving precision diagnostics and treatment for kidney diseases.

摘要

蛋白质糖基化是一种关键的翻译后修饰,通过将聚糖连接到特定位点来影响蛋白质折叠、定位、稳定性和功能相互作用。这一过程对于糖蛋白的生物学功能至关重要,异常糖基化可导致遗传疾病、免疫系统问题和多器官病变。糖蛋白质组学技术的最新进展使蛋白质糖基化研究成为理解肾脏疾病发病机制的关键焦点。本综述全面概述了蛋白质糖基化机制、其生物学作用、分子途径以及在肾脏生理和病理中的重要功能。它特别强调了与免疫球蛋白A肾病、糖尿病肾病、常染色体显性多囊肾病、肾细胞癌和急性肾损伤等肾脏疾病中异常糖基化相关的动态变化和调控网络。它还评估了相关技术和生物标志物的临床应用。此外,它讨论了开发以糖基化为靶点的治疗策略所面临的挑战。未来的研究应集中于阐明肾脏中细胞特异性糖基化调控网络,将糖生物学与多组学方法相结合,以及改善肾脏疾病的精准诊断和治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb7/12368498/34be1f49213f/pbaf017fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb7/12368498/65b60dd23e13/pbaf017gra.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb7/12368498/54b7cfdff5e7/pbaf017fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb7/12368498/82dfad173370/pbaf017fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb7/12368498/29c962748900/pbaf017fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb7/12368498/2cdc1cd6d049/pbaf017fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb7/12368498/486094d333fb/pbaf017fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb7/12368498/34be1f49213f/pbaf017fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb7/12368498/65b60dd23e13/pbaf017gra.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb7/12368498/54b7cfdff5e7/pbaf017fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb7/12368498/82dfad173370/pbaf017fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb7/12368498/29c962748900/pbaf017fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb7/12368498/2cdc1cd6d049/pbaf017fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb7/12368498/486094d333fb/pbaf017fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb7/12368498/34be1f49213f/pbaf017fig6.jpg

相似文献

[1]
Glycosylation in kidney diseases.

Precis Clin Med. 2025-7-11

[2]
Prescription of Controlled Substances: Benefits and Risks

2025-1

[3]
Management of urinary stones by experts in stone disease (ESD 2025).

Arch Ital Urol Androl. 2025-6-30

[4]
Glycomics in Human Diseases and Its Emerging Role in Biomarker Discovery.

Biomedicines. 2025-8-21

[5]
MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols.

Alzheimers Dement. 2021-4

[6]
4-plex quantitative glycoproteomics using glycan/protein-stable isotope labeling in cell culture.

J Proteomics. 2025-1-6

[7]
The role of N6-methyladenosine (mA) RNA methylation modification in kidney diseases: from mechanism to therapeutic potential.

PeerJ. 2025-8-27

[8]
Short-Term Memory Impairment

2025-1

[9]
The role of multi-omics in biomarker discovery, diagnosis, prognosis, and therapeutic monitoring of tissue repair and regeneration processes.

J Orthop Translat. 2025-8-8

[10]
High-throughput N-glycan analysis in aging and inflammaging: State of the art and future directions.

Semin Immunol. 2024-5

本文引用的文献

[1]
Loss of GalNAc-T14 links O-glycosylation defects to alterations in B cell homing in IgA nephropathy.

J Clin Invest. 2025-3-18

[2]
Crosstalk between O-GlcNAcylation and phosphorylation in metabolism: regulation and mechanism.

Cell Death Differ. 2025-3-5

[3]
Multiomics analysis of O-GlcNAcylation in podocytes of diabetic kidney disease.

Diabetes Obes Metab. 2025-5

[4]
Acute kidney injury.

Lancet. 2025-1-18

[5]
Chinese expert consensus on the management of hypertension in adults with type 2 diabetes.

J Evid Based Med. 2024-12

[6]
Advanced Glycation End Products (AGEs) Webinar Meeting Report.

J Diabetes Sci Technol. 2025-3

[7]
Protein O-GlcNAcylation coupled to Hippo signaling drives vascular dysfunction in diabetic retinopathy.

Nat Commun. 2024-10-29

[8]
GALNT3 in Ischemia-Reperfusion Injury of the Kidney.

J Am Soc Nephrol. 2025-3-1

[9]
Clinical glycoproteomics: methods and diseases.

MedComm (2020). 2024-10-4

[10]
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline.

BMJ. 2024-10-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索